Research ExplorerPublicationsRadioprotection of salivary glands by amifostine in high-dos...

Radioprotection of salivary glands by amifostine in high-dose radioiodine therapy.

Standard

Radioprotection of salivary glands by amifostine in high-dose radioiodine therapy. / Bohuslavizki, K H; Brenner, Winfried; Klutmann, S; Hübner, R H; Lassmann, S; Feyerabend, B; Lüttges, J; Tinnemeyer, S; Clausen, M; Henze, E.

In: J NUCL MED, Vol. 39, No. 7, 7, 1998, p. 1237-1242.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Bohuslavizki, KH, Brenner, W, Klutmann, S, Hübner, RH, Lassmann, S, Feyerabend, B, Lüttges, J, Tinnemeyer, S, Clausen, M & Henze, E 1998, 'Radioprotection of salivary glands by amifostine in high-dose radioiodine therapy.', J NUCL MED, vol. 39, no. 7, 7, pp. 1237-1242. <http://www.ncbi.nlm.nih.gov/pubmed/9669401?dopt=Citation>

APA

Bohuslavizki, K. H., Brenner, W., Klutmann, S., Hübner, R. H., Lassmann, S., Feyerabend, B., Lüttges, J., Tinnemeyer, S., Clausen, M., & Henze, E. (1998). Radioprotection of salivary glands by amifostine in high-dose radioiodine therapy. J NUCL MED, 39(7), 1237-1242. [7]. http://www.ncbi.nlm.nih.gov/pubmed/9669401?dopt=Citation

Vancouver

Bohuslavizki KH, Brenner W, Klutmann S, Hübner RH, Lassmann S, Feyerabend B et al. Radioprotection of salivary glands by amifostine in high-dose radioiodine therapy. J NUCL MED. 1998;39(7):1237-1242. 7.

Bibtex

@article{5c9d45c42ab74e2b8673675f31a322b0,
title = "Radioprotection of salivary glands by amifostine in high-dose radioiodine therapy.",
abstract = "Salivary gland impairment after high-dose radioiodine treatment is well recognized. Because differentiated thyroid cancer has a good prognosis, reduction of long-term side effects is important. This study investigated the radioprotective effects of amifostine in animals and humans receiving high-dose radioiodine therapy. METHODS: Quantitative salivary gland scintigraphy was performed in five rabbits before and up to 3 mo after high-dose radioiodine therapy applying 1 GBq 131I. Three animals received 200 mg/kg amifostine before high-dose radioiodine therapy, and two served as controls. All animals were examined histopathologically. Quantitative salivary gland scintigraphy also was performed in 17 patients with differentiated thyroid cancer before and 3 mo after high-dose radioiodine therapy with 6 GBq 131I. Eight patients were treated with 500 mg/m2 amifostine before high-dose radioiodine therapy, and nine served as controls. RESULTS: In two control rabbits, high-dose radioiodine therapy significantly reduced parenchymal function by 63% and 46% in parotid and submandibular glands, respectively. In contrast, there was no significant decrease in parenchymal function in amifostine-treated animals. Histopathologically, lipomatosis was observed in control animals but was negligible in amifostine-treated animals. Similar findings were observed in differentiated thyroid cancer patients. In nine control patients, high-dose radioiodine therapy significantly (p <0.01) reduced parenchymal function by 37% and 31% in parotid and submandibular glands, respectively. Three patients exhibited Grade I (World Health Organization) xerostomia. In contrast, there was no significant decrease in parenchymal function in amifostine-treated patients and no incidence of xerostomia. CONCLUSION: Parenchymal damage in salivary glands induced by high-dose radioiodine therapy can be reduced significantly by amifostine. This may increase the quality of life of patients with differentiated thyroid cancer.",
author = "Bohuslavizki, {K H} and Winfried Brenner and S Klutmann and H{\"u}bner, {R H} and S Lassmann and B Feyerabend and J L{\"u}ttges and S Tinnemeyer and M Clausen and E Henze",
year = "1998",
language = "Deutsch",
volume = "39",
pages = "1237--1242",
journal = "J NUCL MED",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "7",

}

RIS

TY - JOUR

T1 - Radioprotection of salivary glands by amifostine in high-dose radioiodine therapy.

AU - Bohuslavizki, K H

AU - Brenner, Winfried

AU - Klutmann, S

AU - Hübner, R H

AU - Lassmann, S

AU - Feyerabend, B

AU - Lüttges, J

AU - Tinnemeyer, S

AU - Clausen, M

AU - Henze, E

PY - 1998

Y1 - 1998

N2 - Salivary gland impairment after high-dose radioiodine treatment is well recognized. Because differentiated thyroid cancer has a good prognosis, reduction of long-term side effects is important. This study investigated the radioprotective effects of amifostine in animals and humans receiving high-dose radioiodine therapy. METHODS: Quantitative salivary gland scintigraphy was performed in five rabbits before and up to 3 mo after high-dose radioiodine therapy applying 1 GBq 131I. Three animals received 200 mg/kg amifostine before high-dose radioiodine therapy, and two served as controls. All animals were examined histopathologically. Quantitative salivary gland scintigraphy also was performed in 17 patients with differentiated thyroid cancer before and 3 mo after high-dose radioiodine therapy with 6 GBq 131I. Eight patients were treated with 500 mg/m2 amifostine before high-dose radioiodine therapy, and nine served as controls. RESULTS: In two control rabbits, high-dose radioiodine therapy significantly reduced parenchymal function by 63% and 46% in parotid and submandibular glands, respectively. In contrast, there was no significant decrease in parenchymal function in amifostine-treated animals. Histopathologically, lipomatosis was observed in control animals but was negligible in amifostine-treated animals. Similar findings were observed in differentiated thyroid cancer patients. In nine control patients, high-dose radioiodine therapy significantly (p <0.01) reduced parenchymal function by 37% and 31% in parotid and submandibular glands, respectively. Three patients exhibited Grade I (World Health Organization) xerostomia. In contrast, there was no significant decrease in parenchymal function in amifostine-treated patients and no incidence of xerostomia. CONCLUSION: Parenchymal damage in salivary glands induced by high-dose radioiodine therapy can be reduced significantly by amifostine. This may increase the quality of life of patients with differentiated thyroid cancer.

AB - Salivary gland impairment after high-dose radioiodine treatment is well recognized. Because differentiated thyroid cancer has a good prognosis, reduction of long-term side effects is important. This study investigated the radioprotective effects of amifostine in animals and humans receiving high-dose radioiodine therapy. METHODS: Quantitative salivary gland scintigraphy was performed in five rabbits before and up to 3 mo after high-dose radioiodine therapy applying 1 GBq 131I. Three animals received 200 mg/kg amifostine before high-dose radioiodine therapy, and two served as controls. All animals were examined histopathologically. Quantitative salivary gland scintigraphy also was performed in 17 patients with differentiated thyroid cancer before and 3 mo after high-dose radioiodine therapy with 6 GBq 131I. Eight patients were treated with 500 mg/m2 amifostine before high-dose radioiodine therapy, and nine served as controls. RESULTS: In two control rabbits, high-dose radioiodine therapy significantly reduced parenchymal function by 63% and 46% in parotid and submandibular glands, respectively. In contrast, there was no significant decrease in parenchymal function in amifostine-treated animals. Histopathologically, lipomatosis was observed in control animals but was negligible in amifostine-treated animals. Similar findings were observed in differentiated thyroid cancer patients. In nine control patients, high-dose radioiodine therapy significantly (p <0.01) reduced parenchymal function by 37% and 31% in parotid and submandibular glands, respectively. Three patients exhibited Grade I (World Health Organization) xerostomia. In contrast, there was no significant decrease in parenchymal function in amifostine-treated patients and no incidence of xerostomia. CONCLUSION: Parenchymal damage in salivary glands induced by high-dose radioiodine therapy can be reduced significantly by amifostine. This may increase the quality of life of patients with differentiated thyroid cancer.

M3 - SCORING: Zeitschriftenaufsatz

VL - 39

SP - 1237

EP - 1242

JO - J NUCL MED

JF - J NUCL MED

SN - 0161-5505

IS - 7

M1 - 7

ER -